Published in Gene Therapy Weekly, June 6th, 2002
In March 2002, the U.S. Food and Drug Administration (FDA) cleared Abbott Laboratories' use of new clinical data in the test's labeling as providing further evidence of the test's effectiveness in monitoring bladder cancer recurrence.
UroVysion can be used in conjunction with cystoscopy and is the only DNA-based test currently available for monitoring the recurrence of bladder cancer. The UroVysion assay is both highly sensitive...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.